Basit öğe kaydını göster

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

dc.contributor.authorCARTWRIGHT, R.
dc.contributor.authorGATTORNO, M.
dc.contributor.authorSMITH, J.
dc.contributor.authorLESLIE, K. S.
dc.contributor.authorJIMENEZ, S.
dc.contributor.authorMORELL-DUBOIS, S.
dc.contributor.authorDAVIS, N.
dc.contributor.authorPATEL, N.
dc.contributor.authorWIDMER, A.
dc.contributor.authorPREISS, R.
dc.contributor.authorLachmann, H. J.
dc.contributor.authorGül, Ahmet
dc.contributor.authorKUEMMERLE-DESCHNER, Jasmin B.
dc.contributor.authorHACHULLA, E.
dc.contributor.authorHawkins, P. N.
dc.contributor.authorTRAN, T. A.
dc.contributor.authorBader-Meunier, B.
dc.contributor.authorHOYER, J.
dc.date.accessioned2021-03-04T18:16:34Z
dc.date.available2021-03-04T18:16:34Z
dc.date.issued2011
dc.identifier.citationKUEMMERLE-DESCHNER J. B. , HACHULLA E., CARTWRIGHT R., Hawkins P. N. , TRAN T. A. , Bader-Meunier B., HOYER J., GATTORNO M., Gül A., SMITH J., et al., "Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes", ANNALS OF THE RHEUMATIC DISEASES, cilt.70, ss.2095-2102, 2011
dc.identifier.issn0003-4967
dc.identifier.othervv_1032021
dc.identifier.otherav_89d2421d-7d65-4de6-882c-b9f2c199ce4e
dc.identifier.urihttp://hdl.handle.net/20.500.12627/93452
dc.identifier.urihttps://doi.org/10.1136/ard.2011.152728
dc.description.abstractObjective Longer-term effects of prolonged selective interleukin-1 beta blockade with canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic syndrome (CAPS) patients studied to date.
dc.language.isoeng
dc.subjectKlinik Tıp
dc.subjectROMATOLOJİ
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.titleTwo-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes
dc.typeMakale
dc.relation.journalANNALS OF THE RHEUMATIC DISEASES
dc.contributor.departmentEberhard Karls University of Tubingen , ,
dc.identifier.volume70
dc.identifier.issue12
dc.identifier.startpage2095
dc.identifier.endpage2102
dc.contributor.firstauthorID50846


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster